Document is current
Any future updates will be listed below
-
Authors
Balderrama-Brondani, Vania https://orcid.org/0000-0002-9327-9615
Marcal, Leonardo
Moussa, Mohammad Jad
Long, James P.
Varghese, Jeena
Waguespack, Steven G.
Jimenez, Camilo
Graham, Paul H.
Fisher, Sarah B.
Perrier, Nancy
Shah, Amishi Y.
Sheth, Rahul
Zhang, Miao
Campbell, Matthew T.
Habra, Mouhammed Amir https://orcid.org/0000-0002-4148-9637
-
Funding
Funding for this research was provided by:
National Cancer Institute and the National Center for Advancing Translational Sciences of the NIH (CCSG P30CA016672-46 and CCTS UM1TR004906)
The Dan Hund Memorial to Stomp Out Cancer
- License Information
-
More Information
Article History
Received: 9 February 2026
Accepted: 10 July 2026
First Online: 17 July 2026
Change Date: 24 July 2026
Change Type: Update
Change Details: The original version of this paper was updated to present the correct Supplementary Materials.
Declarations
Ethical Approval: This study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Human Investigation Committee (IRB) of University of Texas MD Anderson approved this study (2025-0267). Informed consent was waived.
Consent to Participate and Consent to Publish: Not applicable.
Competing interests: Matthew T. Campbell: Consulting/Advisory Roles: • Eisai, Exelixis, Merck, Pfizer • Trials with Institutional Grant Support: • Exelixis, Pfizer, Janssen, AstraZeneca, Genentech • Non-branded educational programs: • Curio Science, Dava Oncology, MJH LifeSciences, OnViv Cancer Noetic. All other authors report no conflicts of interest.
